ARTICLE | Clinical News
Asenapine regulatory update
February 22, 2010 8:00 AM UTC
Merck submitted a pair of sNDAs to FDA for Saphris asenapine as an adjunct to therapy in patients with mania and as a maintenance treatment for schizophrenia. Saphris is already approved to treat acu...